CeriBell (NASDAQ:CBLL) CTO Raymond Woo Sells 4,887 Shares

Key Points

• CeriBell CTO Raymond Woo sold 4,887 shares at an average price of $24.33, generating approximately $118,901 and reducing his ownership by 2.35% to 203,118 shares.
• CeriBell’s shares recently traded at $23.43, near the upper end of their 52-week range of $10.85 to $25.33. The company reported a quarterly loss of $0.51 per share, worse than estimates, despite revenue exceeding expectations.
• Analyst sentiment remains generally positive, with a consensus rating of “Moderate Buy” and an average price target of $24.40; recent targets range from $26 to $30, although one firm downgraded the stock to “sell.”

CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) CTO Raymond Woo sold 4,887 shares of the company's stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $24.33, for a total transaction of $118,900.71. Following the completion of the transaction, the chief technology officer owned 203,118 shares in the company, valued at approximately $4,941,860.94. This represents a 2.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Raymond Woo also recently made the following trade(s):

• On Friday, August 21st, Raymond Woo sold 1,979 shares of CeriBell stock. The stock was sold at an average price of $24.02, for a total transaction of $47,535.58.

CeriBell Stock Performance

Shares of NASDAQ CBLL traded down $0.98 during trading hours on Thursday, reaching $23.43. 220,126 shares of the stock were exchanged, compared to its average volume of 327,873. The company has a debt-to-equity ratio of 0.16, a quick ratio of 8.79 and a current ratio of 9.18. The stock's fifty day simple moving average is $21.03 and its 200 day simple moving average is $19.61. CeriBell, Inc. has a 52 week low of $10.85 and a 52 week high of $25.33. The firm has a market capitalization of $899.24 million, a price-to-earnings ratio of -13.31 and a beta of 0.95.

CeriBell (NASDAQ:CBLL - Get Free Report) last posted its earnings results on Monday, August 10th. The company reported ($0.51) earnings per share for the quarter, missing analysts' consensus estimates of ($0.47) by ($0.04). CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%.The firm had revenue of $28.10 million for the quarter, compared to analyst estimates of $27.28 million. Sell-side analysts predict that CeriBell, Inc. will post -1.96 EPS for the current year.

Institutional Investors Weigh In On CeriBell

A number of hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. grew its holdings in shares of CeriBell by 6,424.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 380,003 shares of the company's stock valued at $7,117,000 after purchasing an additional 374,179 shares during the last quarter. Rhumbline Advisers boosted its position in CeriBell by 109.9% in the second quarter. Rhumbline Advisers now owns 32,806 shares of the company's stock valued at $614,000 after buying an additional 17,177 shares in the last quarter. New York State Common Retirement Fund grew its stake in shares of CeriBell by 148.6% during the second quarter. New York State Common Retirement Fund now owns 8,700 shares of the company's stock worth $163,000 after buying an additional 5,200 shares during the last quarter. Quantbot Technologies LP increased its holdings in shares of CeriBell by 70.3% during the second quarter. Quantbot Technologies LP now owns 15,504 shares of the company's stock worth $290,000 after buying an additional 6,401 shares in the last quarter. Finally, Invesco Ltd. acquired a new stake in shares of CeriBell during the 2nd quarter valued at $197,000.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on CBLL shares. BTIG Research increased their price target on CeriBell from $28.00 to $30.00 and gave the stock a "buy" rating in a research report on Tuesday, August 18th. Raymond James Financial reaffirmed a "strong-buy" rating and issued a $29.00 price target on shares of CeriBell in a research note on Thursday, September 3rd. Barclays raised shares of CeriBell to a "neutral" rating in a report on Tuesday, August 18th. Canaccord Genuity Group increased their price target on shares of CeriBell from $25.00 to $26.00 and gave the stock a "buy" rating in a research report on Tuesday, August 11th. Finally, Weiss Ratings downgraded CeriBell from a "sell (d-)" rating to a "sell (e+)" rating in a report on Friday, August 28th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $24.40.

CeriBell Company Profile

CeriBell Corp NASDAQ: CBLL is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell's solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company's product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.